Zhao Jincun, Perera Ranawaka A P M, Kayali Ghazi, Meyerholz David, Perlman Stanley, Peiris Malik
Department of Microbiology, University of Iowa, Iowa City, Iowa, USA State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
The School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.
J Virol. 2015 Jun;89(11):6117-20. doi: 10.1128/JVI.00446-15. Epub 2015 Mar 18.
Middle East respiratory syndrome (MERS) is a highly lethal pulmonary infection. Serum from convalescent MERS patients may provide some benefit but is not readily available. In contrast, nearly all camels in the Middle East have been infected with MERS-CoV. Here, we show that sera obtained from MERS-immune camels augment the kinetics of MERS-CoV clearance and reduce the severity of pathological changes in infected lungs, with efficacy proportional to the titer of MERS-CoV-neutralizing serum antibody.
Middle East respiratory syndrome, caused by a coronavirus, is highly lethal, with a case fatality rate of 35 to 40%. No specific therapy is available, and care is generally supportive. One promising approach is passive administration of sera from convalescent human MERS patients or other animals to exposed or infected patients. The vast majority of, if not all, camels in the Middle East have been infected with MERS-CoV, and some contain high titers of antibody to the virus. Here, we show that this antibody is protective if delivered either prophylactically or therapeutically to mice infected with MERS-CoV, indicating that this may be a useful intervention in infected patients.
中东呼吸综合征（MERS）是一种致死率很高的肺部感染疾病。康复期MERS患者的血清可能会有一定益处，但不易获取。相比之下，中东地区几乎所有骆驼都感染过中东呼吸综合征冠状病毒（MERS-CoV）。在此，我们表明，从对MERS具有免疫力的骆驼身上获取的血清可加快MERS-CoV清除动力学，并减轻受感染肺部的病理变化严重程度，其疗效与MERS-CoV中和血清抗体滴度成正比。
由冠状病毒引起的中东呼吸综合征致死率很高，病死率为35%至40%。目前尚无特效疗法，治疗通常为支持性治疗。一种有前景的方法是向暴露或感染的患者被动输注康复期人类MERS患者或其他动物的血清。中东地区绝大多数（即便不是全部）骆驼都感染过MERS-CoV，其中一些含有高滴度的该病毒抗体。在此，我们表明，这种抗体对感染MERS-CoV的小鼠进行预防性或治疗性给药时具有保护作用，这表明这可能是对感染患者的一种有效干预措施。
